1
WGU D116 Advanced Pharmacology OA Exam
2026/2027 Actual Exam - 500 Questions with
Detailed Rationales | 100% Verified Graded A+
Pass Guaranteed - A+ Graded
Section 1: Pharmacokinetics & Pharmacodynamics Fundamentals (Questions 1-40)
Q1: A patient asks why their oral morphine isn't working as well as the IV morphine they
received in the hospital. What is the primary pharmacokinetic reason?
A. Faster excretion
B. First-pass metabolism
C. Higher protein binding
D. Delayed onset
Correct Answer: B
Rationale: Oral morphine undergoes significant first-pass hepatic metabolism, drastically
reducing its systemic bioavailability compared to the IV route. Faster excretion (A) is incorrect
as IV drugs clear faster; delayed onset (D) is true but does not explain the reduced overall
efficacy.
Q2: A drug with a high therapeutic index (TI) is prescribed. What does this indicate about the
drug?
A. It has a high risk of toxicity
B. The toxic dose is very close to the effective dose
C. The toxic dose is much higher than the effective dose
D. It requires strict therapeutic drug monitoring
Correct Answer: C
Rationale: A high TI means there is a wide margin of safety between the effective dose and the
toxic dose. Low TI (B) requires monitoring (D), making those options incorrect for a high TI
drug.
,2
Q3: Which cytochrome P450 enzyme is responsible for metabolizing the widest variety of drugs?
A. CYP2D6
B. CYP3A4
C. CYP1A2
D. CYP2C9
Correct Answer: B
Rationale: CYP3A4 is the most abundant and versatile CYP450 enzyme in the liver, responsible
for metabolizing over 50% of all drugs. CYP2D6 (A) is polymorphic but handles fewer drugs
overall.
Q4: A patient with liver cirrhosis is prescribed a highly protein-bound drug (99%). What
pharmacokinetic change is most likely?
A. Decreased volume of distribution
B. Increased free drug concentration
C. Increased metabolism of the drug
D. Decreased renal excretion
Correct Answer: B
Rationale: Cirrhosis leads to hypoalbuminemia, reducing available protein binding sites and
increasing the free, pharmacologically active fraction of the drug. Decreased metabolism (C) also
occurs but the immediate binding issue causes increased free drug (B).
Q5: A drug is a partial agonist at a specific receptor. What is its primary clinical characteristic?
A. Produces a maximal response greater than a full agonist
B. Produces a submaximal response even when all receptors are occupied
C. Blocks the receptor completely
D. Has no intrinsic activity
Correct Answer: B
Rationale: Partial agonists have intrinsic activity but cannot elicit the same maximum response
as a full agonist, regardless of receptor occupancy. Antagonists (C/D) have no intrinsic activity.
,3
Q6: How many half-lives are required for a drug to reach approximately 94% of its steady-state
concentration?
A. 2
B. 3
C. 4
D. 5
Correct Answer: C
Rationale: It takes approximately 4 to 5 half-lives to reach steady state; specifically, 4 half-lives
equals 93.75% (rounded to 94%). Three half-lives (B) is 87.5%, and five (D) is 96.9%.
Q7: Which route of administration completely bypasses the first-pass effect?
A. Oral
B. Sublingual
C. Intramuscular
D. Rectal
Correct Answer: B
Rationale: Sublingual administration absorbs directly into the systemic circulation via the highly
vascularized sublingual mucosa, completely bypassing the hepatic portal system. IM (C) and
Rectal (D) undergo partial first-pass metabolism.
Q8: An antagonist drug binds to a receptor but does not activate it, and its effects can be
overcome by increasing the concentration of an agonist. This is a:
A. Noncompetitive antagonist
B. Irreversible antagonist
C. Competitive antagonist
D. Partial agonist
Correct Answer: C
, 4
Rationale: Competitive antagonists bind reversibly to the same site as the agonist, competing for
receptors; high agonist concentrations can outcompete the antagonist. Noncompetitive (A)
cannot be overcome.
Q9: What is the definition of bioavailability?
A. The rate at which a drug is eliminated
B. The fraction of an administered drug that reaches the systemic circulation unchanged
C. The amount of drug bound to plasma proteins
D. The volume of blood cleared of drug per unit time
Correct Answer: B
Rationale: Bioavailability (F) measures the proportion of the unchanged drug that reaches
systemic circulation and is available at the site of action. Clearance (D) is the volume cleared,
not bioavailability.
Q10: A patient taking a CYP3A4 inhibitor starts a new medication metabolized by CYP3A4.
What is the expected outcome?
A. Decreased plasma levels of the new drug
B. Increased risk of toxicity from the new drug
C. No change in drug levels
D. Accelerated excretion of the new drug
Correct Answer: B
Rationale: Inhibiting the metabolic enzyme slows the breakdown of the new drug, leading to
increased plasma concentrations and a higher risk of toxicity. Inducers (A) would decrease
levels.
Q11: A drug exhibits zero-order pharmacokinetics. Which statement is true?
A. A constant amount of drug is eliminated per unit time
B. A constant fraction of drug is eliminated per unit time
C. Elimination rate is dependent on plasma concentration
WGU D116 Advanced Pharmacology OA Exam
2026/2027 Actual Exam - 500 Questions with
Detailed Rationales | 100% Verified Graded A+
Pass Guaranteed - A+ Graded
Section 1: Pharmacokinetics & Pharmacodynamics Fundamentals (Questions 1-40)
Q1: A patient asks why their oral morphine isn't working as well as the IV morphine they
received in the hospital. What is the primary pharmacokinetic reason?
A. Faster excretion
B. First-pass metabolism
C. Higher protein binding
D. Delayed onset
Correct Answer: B
Rationale: Oral morphine undergoes significant first-pass hepatic metabolism, drastically
reducing its systemic bioavailability compared to the IV route. Faster excretion (A) is incorrect
as IV drugs clear faster; delayed onset (D) is true but does not explain the reduced overall
efficacy.
Q2: A drug with a high therapeutic index (TI) is prescribed. What does this indicate about the
drug?
A. It has a high risk of toxicity
B. The toxic dose is very close to the effective dose
C. The toxic dose is much higher than the effective dose
D. It requires strict therapeutic drug monitoring
Correct Answer: C
Rationale: A high TI means there is a wide margin of safety between the effective dose and the
toxic dose. Low TI (B) requires monitoring (D), making those options incorrect for a high TI
drug.
,2
Q3: Which cytochrome P450 enzyme is responsible for metabolizing the widest variety of drugs?
A. CYP2D6
B. CYP3A4
C. CYP1A2
D. CYP2C9
Correct Answer: B
Rationale: CYP3A4 is the most abundant and versatile CYP450 enzyme in the liver, responsible
for metabolizing over 50% of all drugs. CYP2D6 (A) is polymorphic but handles fewer drugs
overall.
Q4: A patient with liver cirrhosis is prescribed a highly protein-bound drug (99%). What
pharmacokinetic change is most likely?
A. Decreased volume of distribution
B. Increased free drug concentration
C. Increased metabolism of the drug
D. Decreased renal excretion
Correct Answer: B
Rationale: Cirrhosis leads to hypoalbuminemia, reducing available protein binding sites and
increasing the free, pharmacologically active fraction of the drug. Decreased metabolism (C) also
occurs but the immediate binding issue causes increased free drug (B).
Q5: A drug is a partial agonist at a specific receptor. What is its primary clinical characteristic?
A. Produces a maximal response greater than a full agonist
B. Produces a submaximal response even when all receptors are occupied
C. Blocks the receptor completely
D. Has no intrinsic activity
Correct Answer: B
Rationale: Partial agonists have intrinsic activity but cannot elicit the same maximum response
as a full agonist, regardless of receptor occupancy. Antagonists (C/D) have no intrinsic activity.
,3
Q6: How many half-lives are required for a drug to reach approximately 94% of its steady-state
concentration?
A. 2
B. 3
C. 4
D. 5
Correct Answer: C
Rationale: It takes approximately 4 to 5 half-lives to reach steady state; specifically, 4 half-lives
equals 93.75% (rounded to 94%). Three half-lives (B) is 87.5%, and five (D) is 96.9%.
Q7: Which route of administration completely bypasses the first-pass effect?
A. Oral
B. Sublingual
C. Intramuscular
D. Rectal
Correct Answer: B
Rationale: Sublingual administration absorbs directly into the systemic circulation via the highly
vascularized sublingual mucosa, completely bypassing the hepatic portal system. IM (C) and
Rectal (D) undergo partial first-pass metabolism.
Q8: An antagonist drug binds to a receptor but does not activate it, and its effects can be
overcome by increasing the concentration of an agonist. This is a:
A. Noncompetitive antagonist
B. Irreversible antagonist
C. Competitive antagonist
D. Partial agonist
Correct Answer: C
, 4
Rationale: Competitive antagonists bind reversibly to the same site as the agonist, competing for
receptors; high agonist concentrations can outcompete the antagonist. Noncompetitive (A)
cannot be overcome.
Q9: What is the definition of bioavailability?
A. The rate at which a drug is eliminated
B. The fraction of an administered drug that reaches the systemic circulation unchanged
C. The amount of drug bound to plasma proteins
D. The volume of blood cleared of drug per unit time
Correct Answer: B
Rationale: Bioavailability (F) measures the proportion of the unchanged drug that reaches
systemic circulation and is available at the site of action. Clearance (D) is the volume cleared,
not bioavailability.
Q10: A patient taking a CYP3A4 inhibitor starts a new medication metabolized by CYP3A4.
What is the expected outcome?
A. Decreased plasma levels of the new drug
B. Increased risk of toxicity from the new drug
C. No change in drug levels
D. Accelerated excretion of the new drug
Correct Answer: B
Rationale: Inhibiting the metabolic enzyme slows the breakdown of the new drug, leading to
increased plasma concentrations and a higher risk of toxicity. Inducers (A) would decrease
levels.
Q11: A drug exhibits zero-order pharmacokinetics. Which statement is true?
A. A constant amount of drug is eliminated per unit time
B. A constant fraction of drug is eliminated per unit time
C. Elimination rate is dependent on plasma concentration
